Galectin Therapeutics (GALT) 10-Q2008 Q1 Quarterly report

Content analysis

Filed: 15 May 08, 12:00am

Date: May 15, 2008

/s/ Anthony D. Squeglia

Anthony D. Squeglia

Chief Financial Officer

(Principal Financial Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absence, accumulated, acute, annum, arising, assigned, average, awarded, biologic, biopharmaceutical, Brigham, caution, chemical, chronic, collagen, Commonwealth, competing, consecutive, covering, Custom, decided, declaratory, discharged, dividend, economic, EITF, Emerging, enrichment, entity, estate, exit, fee, Force, found, framework, free, government, health, history, Hospital, housing, hypothetical, identical, indemnification, inflammatory, institutional, kidney, lead, life, liver, Master, Medicine, merger, microbial, Mount, nonfinancial, nonrecurring, nonrefundable, orderly, personnel, pipeline, prosecuting, quality, quoted, reclassification, Reform, reimbursement, reliance, reorganization, School, Settled, Sinai, sought, split, Street, study, subscription, suggested, Summer, survival, Task, transfer, underlying, undue, unjust, unobservable, Unregistered, vitro, weighted, Women

Removed: accelerate, Administration, announced, answered, application, approved, audit, authority, Avastin, binomial, body, carry, Chapter, charge, classification, Code, compound, concentration, continuing, convert, counterclaim, creating, credited, dated, default, delivery, derecognition, detail, directly, discount, discussed, dispose, document, dollar, entirety, equivalent, estimate, evaluating, excipient, exempt, expanded, expressed, fixed, Food, functional, guidance, harbor, implied, IND, indemnify, initially, investigational, involve, irrevocably, iv, judge, largest, leave, Leucovorin, limitation, liquidation, measure, measurement, NDA, offer, oncology, opening, opposition, Original, ownership, performance, petition, preferable, presented, proceeding, project, proposed, protocol, ranged, receive, recognition, recognize, redeem, redeemed, redemption, reduction, register, relevant, repaid, resell, responded, restricted, retained, retention, return, safe, schedule, scheduled, seek, specific, Specifically, spending, stayed, submission, subsequently, summarize, supplemental, supply, sustained, target, targeting, testing, threshold, timely, tolerance, uncertain, undertaken, underwritten, unexercised, unknown, USPTO, volume, voluntary

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GALT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Pro-Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony D. Squeglia, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pro-Pharmaceuticals, Inc. and will be retained by Pro-Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.